Skip to main content

POZ: Integrate Adult and Pediatric HIV Care to Ease Youth Transition to Adult Care

June 07, 2021 | Heather Boerner

Patrick Ryscavage, MD

Embedding an adult HIV medicine clinician and care navigator into a Baltimore pediatric HIV clinic led to 95% of young people remaining engaged in adult care one year after transition, according to a report in AIDS Care.

While young people with HIV are leading the way in so many aspects of HIV advocacy, clinical care can sometimes lag. When teens with HIV transfer from the pediatric HIV care they’ve received all their lives to adult HIV clinics, they are are more at risk of disengaging from care. As it is, teens and young adults have traditionally been less likely to be connected to HIV care.

So Patrick Ryscavage, MD, an assistant professor of pediatrics and medicine at the Institute for Human Virology at University of Maryland School of Medicine, and colleagues decided to catalog what, if anything, changed in terms of care engagement after transition to adult care after they integrated an adult HIV provider and a care navigator into their pediatric HIV clinic.

The University of Maryland HIV Structured Transition EmPowerment (STEP) program, which went into effect in July 2017, included a specific clinic for transition to adult care that was located at the pediatric clinic but staffed by an adult care provider and a navigator. It also included coordination with the pediatric care team, individualized transition plans for each participant, a pre-transition assessment that included the whole team and a transition visit at the adult clinic that included the STEP program providers from the pediatric clinic.

To assess whether the new approach changed post-transition engagement in care, Ryscavage and colleagues followed the 34 teens who transitioned to adult care between 2017 and 2020 and then compared rates of continued care at the adult clinic against data on transition and retention in care from the pre-STEP era, 2004 to 2012. Most STEP program participants (71%) were young men, 94% were Black, nearly half were living with a mental health diagnosis and 38% were using substances.

Read the full story

Contact

Institute of Human Virology
Nora Samaranayake
Director of Marketing and Public Relations
(410) 706-8614 (phone)
(410) 706-1952 (fax)
nsamaranayake@ihv.umaryland.edu

Related stories

    Tuesday, July 06, 2021

    UM School of Medicine Researchers Receive NIH Avant-Garde Award for Out-Of-Box Concept to Cure HIV and Treat Co-Existing Addiction

    Linda Chang, MD, MS, Professor of Diagnostic Radiology & Nuclear Medicine at the University of Maryland School of Medicine (UMSOM), received the National Institute on Drug Abuse (NIDA) 2021 Avant-Garde Award (DP1) for HIV/AIDS and Substance Use Disorder Research, a National Institutes of Health (NIH) Director’s Pioneer Award. This prestigious award supports researchers with exceptional creativity, who propose high-impact research with the potential to be transformative to the field. She will work with Institute for Human Virology (IHV) researchers for this project.


    Thursday, May 27, 2021

    Baltimore Sun: Maryland researchers study whether HIV cure can come from infusing patients with genetically modified ‘super T cells’

    A week ago, a Washington, D.C., man in his 30s with HIV became the first person to be infused with a heaping load of his own genetically modified cells that a Maryland biotech firm believes one day could lead to the elusive cure for the disease. American Gene Technologies’ method involves taking T cells out of a person’s blood and genetically modifying them in the lab to resist infection before they are reinfused. C. David Pauza is the company’s chief science officer and a former professor and researcher at the University of Maryland School of Medicine’s Institute for Human Virology. Another center evaluating entering the study is Maryland’s Institute for Human Virology, confirmed its co-founder and director, Dr. Robert Gallo, who is internationally regarded for his role in discovering HIV and developing a blood test to detect it.


    Thursday, April 01, 2021

    A Statement from the Leadership of the University of Maryland School of Medicine’s Institute of Human Virology on the Passing of Dr. John Martin

    The Institute of Human Virology at the University of Maryland School of Medicine mourns the passing of IHV 2014 Lifetime Achievement Public Service Awardee and 2017 Annual Marlene and Stewart Greenebaum Lecturer, John Martin, PhD. Dr. Martin was a leader in supporting access to life-saving anti-HIV medications that although still under patent were made widely and affordably available to millions around the world infected with HIV, and for prevention through pre-exposure drug therapy. He was a tremendous clinical scientist, businessman, global public health leader, philanthropist, and good friend.


    Monday, August 03, 2020

    Infectious Disease Special Edition: COVID-19 and HIV: Was It a Deadly Mix?

    Social distancing is one of the curses of COVID-19, and may fall more heavily on people with HIV than on those without this burden. “People with HIV, and in particular certain subsets of that group—the LGBTQ community, older adults aging with HIV, etc.—face more mental health issues than the general population,” said Sarah Schmalzle, MD, an assistant professor of medicine at the Institute of Human Virology, University of Maryland School of Medicine, in Baltimore. “Many of our patients also already face significant isolation and loneliness due to a combination of HIV stigma, losses of friends and family to HIV, and aging.”


    Tuesday, July 07, 2020

    Courthouse News Service: Global Progress on Ending HIV/AIDS Derailed by Covid-19

    A United Nations program aimed at eliminating HIV/AIDS released a report Monday showing that the global response to the epidemic has fallen far short of goals set for 2020, in large part due to the coronavirus pandemic.


    Monday, June 24, 2019

    UM School of Medicine's Institute of Human Virology Awarded $40 Million Grant to Conduct HIV Population Surveys

    Man Charurat, MD, Professor of Medicine, Director, Center for International Health, Education, and Biosecurity (CIHEB), and Director, Division of Epidemiology and Prevention, Institute of Human Virology (IHV) at the University of Maryland School of Medicine (UMSOM), has been awarded a five-year grant from the U.S. Centers for Disease Control and Prevention (CDC) to conduct HIV population-based HIV impact assessments worldwide to measure the progress towards the control of the HIV epidemic


    Wednesday, May 01, 2019

    Large National Survey Shows Smaller HIV Epidemic in Nigeria Than Once Thought and Highlights Key Gaps

    (CDC) The Government of Nigeria, the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR), CDC, and the University of Maryland School of Medicine released new data from the Nigeria HIV/AIDS Indicator and Impact Survey (NAIIS), one of the largest population-based HIV/AIDS household surveys ever conducted. The NAIIS directly measured HIV prevalence and viral load suppression. According to the NAIIS results, the HIV prevalence in Nigeria is lower than previously thought, allowing the country to focus on providing services to the areas of greatest need to control the HIV epidemic.


    Wednesday, August 02, 2017

    UM School of Medicine Receives $2 Million Grant for HIV Research in Malawi

    The University of Maryland School of Medicine’s (UM SOM) Institute for Global Health (IGH) and the Institute of Human Virology (IHV) have been awarded a $2 million five-year grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development to study the impact exposure to HIV has on the immune systems of infants in utero and how those changes impact the ability of infants to fight off infections after birth.


    Tuesday, October 25, 2016

    "A Call to End HIV/AIDS in America" IHV Director Dr. Robert Gallo's Op-Ed in the Huffington Post

    As the new Administration is presented with great challenges facing the United States, one will be a longtime foe, the U.S. HIV/AIDS epidemic. Since President Barack Obama was elected in 2008, I have publicly called on our country’s leaders to utilize the largest global health initiative in history - the President’s Emergency Plan for AIDS Relief (PEPFAR) - as a model to address the U.S. epidemic.